STOCK TITAN

[Form 4] Kestra Medical Technologies, Ltd. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Jeffrey Lawrence Schwartz, a partner at Bain Capital Investors and a director/10% owner of Kestra Medical Technologies, acquired 10,909 restricted stock units (RSUs) on 09/04/2025. Each RSU converts to one common share and the RSUs vest on 09/04/2026 subject to continued service. After the reported acquisition Mr. Schwartz beneficially owns 10,909 shares directly and 27,019,225 shares indirectly, the latter held by Bain Charger Holdings, L.P. and West Affum Holdings, L.P., with Bain Capital entities holding controlling interests. Mr. Schwartz disclaims beneficial ownership except to the extent of his pecuniary interest.

Jeffrey Lawrence Schwartz, socio di Bain Capital Investors e amministratore/proprietario del 10% di Kestra Medical Technologies, ha acquisito 10.909 unità di azioni vincolate (RSU) il 04/09/2025. Ogni RSU si converte in una azione ordinaria e le RSU maturano il 04/09/2026 soggette al mantenimento del rapporto di lavoro. Dopo l'acquisizione comunicata, il signor Schwartz possiede beneficiariamente 10.909 azioni direttamente e 27.019.225 azioni indirettamente, queste ultime detenute da Bain Charger Holdings, L.P. e West Affum Holdings, L.P., con entità di Bain Capital che detengono interessi di controllo. Il signor Schwartz declina la proprietà beneficiaria eccetto nella misura del suo interesse pecuniario.

Jeffrey Lawrence Schwartz, socio de Bain Capital Investors y director/propietario del 10% de Kestra Medical Technologies, adquirió 10.909 unidades de acciones restringidas (RSU) el 04/09/2025. Cada RSU se convierte en una acción ordinaria y las RSU se consolidan el 04/09/2026 sujetas a la continuación del servicio. Tras la adquisición comunicada, el Sr. Schwartz posee beneficiariamente 10.909 acciones de forma directa y 27.019.225 acciones de forma indirecta, estas últimas en poder de Bain Charger Holdings, L.P. y West Affum Holdings, L.P., con entidades de Bain Capital que mantienen intereses de control. El Sr. Schwartz renuncia a la propiedad beneficiaria salvo en la medida de su interés pecuniario.

Jeffrey Lawrence Schwartz는 Bain Capital Investors의 파트너이자 Kestra Medical Technologies의 이사/10% 소유자로서 2025년 9월 4일 10,909개의 제한부 주식 단위(RSU)를 취득했습니다. 각 RSU는 보통주 1주로 전환되며, RSU는 계속 근무를 조건으로 2026년 9월 4일에 보유권이 확정됩니다. 보고된 취득 이후 Schwartz 씨는 직접적으로 10,909주간접적으로 27,019,225주를 실질적으로 보유하고 있으며, 간접 보유분은 Bain Charger Holdings, L.P.와 West Affum Holdings, L.P.가 보유하고 있고 Bain Capital 계열사가 지배적 지분을 보유하고 있습니다. Schwartz 씨는 자신의 금전적 이익이 미치는 범위를 제외하고는 실질적 소유권을 부인합니다.

Jeffrey Lawrence Schwartz, associé chez Bain Capital Investors et administrateur/propriétaire à hauteur de 10% de Kestra Medical Technologies, a acquis le 04/09/2025 10 909 unités d'actions restreintes (RSU). Chaque RSU se convertit en une action ordinaire et les RSU deviendront acquises le 04/09/2026 sous réserve de la poursuite du service. Après l'acquisition signalée, M. Schwartz détient bénéficiairement 10 909 actions directement et 27 019 225 actions indirectement, ces dernières détenues par Bain Charger Holdings, L.P. et West Affum Holdings, L.P., les entités de Bain Capital détenant les intérêts de contrôle. M. Schwartz décline toute propriété bénéficiaire sauf dans la mesure de son intérêt pécuniaire.

Jeffrey Lawrence Schwartz, Partner bei Bain Capital Investors und Direktor/10%-Eigentümer von Kestra Medical Technologies, erwarb am 04.09.2025 10.909 Restricted Stock Units (RSUs). Jede RSU wandelt sich in eine Stammaktie um und die RSUs werden am 04.09.2026 unter der Bedingung fortgesetzter Tätigkeit fällig. Nach der gemeldeten Erwerbung besitzt Herr Schwartz wirtschaftlich 10.909 Aktien direkt und 27.019.225 Aktien indirekt, letztere gehalten von Bain Charger Holdings, L.P. und West Affum Holdings, L.P., wobei Bain Capital-Gesellschaften Mehrheitsinteressen innehaben. Herr Schwartz weist eine wirtschaftliche Eigentümerschaft ab, außer insoweit sein pecuniäres Interesse betroffen ist.

Positive
  • Director alignment: Time-vesting RSUs align the reporting persons incentives with long-term shareholder value.
  • Full disclosure: The filing discloses indirect holdings and the ownership structure through Bain-affiliated entities.
Negative
  • Concentration of control: A large block of 27,019,225 indirect shares is held by Bain-affiliated vehicles, indicating concentrated influence which may concern some investors.

Insights

TL;DR: Routine insider equity grant; signals alignment but minimal immediate market impact given large existing indirect holdings.

The reported grant of 10,909 RSUs is a standard long-term compensation vehicle tying executive incentives to equity performance. Vesting is time-based one year out, which supports retention. The incremental economic stake is small relative to the reported 27,019,225 indirect shares tied to Bain-affiliated vehicles, so the marginal effect on control or market float is negligible. For investors, this demonstrates continued alignment of the director with shareholder outcomes but does not represent a material change in ownership or control.

TL;DR: Governance-wise this is a customary director grant; disclosure clarifies indirect ownership through Bain entities.

The Form 4 properly discloses both the time-vesting RSUs and the web of indirect holdings through Bain Charger and West Affum, preserving transparency about potential shared voting/dispositive power. The filing includes the required disclaimer of beneficial ownership except for pecuniary interest, which is standard when ownership is held in affiliated partnerships. No unusual derivative or disposition activity is reported, indicating no immediate governance changes.

Jeffrey Lawrence Schwartz, socio di Bain Capital Investors e amministratore/proprietario del 10% di Kestra Medical Technologies, ha acquisito 10.909 unità di azioni vincolate (RSU) il 04/09/2025. Ogni RSU si converte in una azione ordinaria e le RSU maturano il 04/09/2026 soggette al mantenimento del rapporto di lavoro. Dopo l'acquisizione comunicata, il signor Schwartz possiede beneficiariamente 10.909 azioni direttamente e 27.019.225 azioni indirettamente, queste ultime detenute da Bain Charger Holdings, L.P. e West Affum Holdings, L.P., con entità di Bain Capital che detengono interessi di controllo. Il signor Schwartz declina la proprietà beneficiaria eccetto nella misura del suo interesse pecuniario.

Jeffrey Lawrence Schwartz, socio de Bain Capital Investors y director/propietario del 10% de Kestra Medical Technologies, adquirió 10.909 unidades de acciones restringidas (RSU) el 04/09/2025. Cada RSU se convierte en una acción ordinaria y las RSU se consolidan el 04/09/2026 sujetas a la continuación del servicio. Tras la adquisición comunicada, el Sr. Schwartz posee beneficiariamente 10.909 acciones de forma directa y 27.019.225 acciones de forma indirecta, estas últimas en poder de Bain Charger Holdings, L.P. y West Affum Holdings, L.P., con entidades de Bain Capital que mantienen intereses de control. El Sr. Schwartz renuncia a la propiedad beneficiaria salvo en la medida de su interés pecuniario.

Jeffrey Lawrence Schwartz는 Bain Capital Investors의 파트너이자 Kestra Medical Technologies의 이사/10% 소유자로서 2025년 9월 4일 10,909개의 제한부 주식 단위(RSU)를 취득했습니다. 각 RSU는 보통주 1주로 전환되며, RSU는 계속 근무를 조건으로 2026년 9월 4일에 보유권이 확정됩니다. 보고된 취득 이후 Schwartz 씨는 직접적으로 10,909주간접적으로 27,019,225주를 실질적으로 보유하고 있으며, 간접 보유분은 Bain Charger Holdings, L.P.와 West Affum Holdings, L.P.가 보유하고 있고 Bain Capital 계열사가 지배적 지분을 보유하고 있습니다. Schwartz 씨는 자신의 금전적 이익이 미치는 범위를 제외하고는 실질적 소유권을 부인합니다.

Jeffrey Lawrence Schwartz, associé chez Bain Capital Investors et administrateur/propriétaire à hauteur de 10% de Kestra Medical Technologies, a acquis le 04/09/2025 10 909 unités d'actions restreintes (RSU). Chaque RSU se convertit en une action ordinaire et les RSU deviendront acquises le 04/09/2026 sous réserve de la poursuite du service. Après l'acquisition signalée, M. Schwartz détient bénéficiairement 10 909 actions directement et 27 019 225 actions indirectement, ces dernières détenues par Bain Charger Holdings, L.P. et West Affum Holdings, L.P., les entités de Bain Capital détenant les intérêts de contrôle. M. Schwartz décline toute propriété bénéficiaire sauf dans la mesure de son intérêt pécuniaire.

Jeffrey Lawrence Schwartz, Partner bei Bain Capital Investors und Direktor/10%-Eigentümer von Kestra Medical Technologies, erwarb am 04.09.2025 10.909 Restricted Stock Units (RSUs). Jede RSU wandelt sich in eine Stammaktie um und die RSUs werden am 04.09.2026 unter der Bedingung fortgesetzter Tätigkeit fällig. Nach der gemeldeten Erwerbung besitzt Herr Schwartz wirtschaftlich 10.909 Aktien direkt und 27.019.225 Aktien indirekt, letztere gehalten von Bain Charger Holdings, L.P. und West Affum Holdings, L.P., wobei Bain Capital-Gesellschaften Mehrheitsinteressen innehaben. Herr Schwartz weist eine wirtschaftliche Eigentümerschaft ab, außer insoweit sein pecuniäres Interesse betroffen ist.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Schwartz Jeffrey Lawrence

(Last) (First) (Middle)
C/O BAIN CAPITAL INVESTORS, LLC
200 CLARENDON STREET

(Street)
BOSTON MA 02116

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 09/04/2025 A 10,909(1) A (1) 10,909 D
Common Shares 27,019,225 I See footnote(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The reported securities represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest on September 4, 2026, subject to the Reporting Person's continued service through such date.
2. Represents 7,109,944 common shares of the Issuer held directly by Bain Charger Holdings, L.P. ("Bain Charger') and 19,909,281 common shares of the Issuer held directly by West Affum Holdings, L.P. ("West Affum"). Bain Charger is the sole shareholder of West Affum GP Ltd., which is the general partner of West Affum. Mr. Schwartz is a Partner of Bain Capital Investors, LLC, which is the general partner of Bain Charger. As a result, Mr. Schwartz may be deemed to share voting and dispositive power with respect to the securities held by Bain Charger and West Affum. Mr. Schwartz disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
/s/ Jeffrey Schwartz 09/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Jeffrey Lawrence Schwartz report on Form 4 for KMTS?

He reported an acquisition of 10,909 RSUs that convert one-for-one to common shares and vest on 09/04/2026 subject to continued service.

How many Kestra Medical (KMTS) shares does Mr. Schwartz beneficially own after the transaction?

He beneficially owns 10,909 shares directly and 27,019,225 shares indirectly through Bain Charger and West Affum entities.

What is the nature of the 10,909 securities reported?

They are restricted stock units (RSUs), each entitling the holder to one common share upon vesting.

When do the reported RSUs vest?

The RSUs will vest on 09/04/2026 provided the reporting person remains in service through that date.

Does Mr. Schwartz claim full beneficial ownership of the indirect holdings?

No. He disclaims beneficial ownership of the indirect holdings except to the extent of his pecuniary interest, while noting he may be deemed to share voting and dispositive power.
KESTRA MED TECHNOLOGIES LTD

NASDAQ:KMTS

KMTS Rankings

KMTS Latest News

KMTS Latest SEC Filings

KMTS Stock Data

934.03M
21.06M
6.37%
94.15%
4.04%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
KIRKLAND